<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Zura Bio Limited Class A Ordinary Shares — News on 6ix</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares</link>
<description>Latest news and press releases for Zura Bio Limited Class A Ordinary Shares on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 19 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/zura-bio-limited-class-a-ordinary-shares" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835dda778dffbe2df124d21.webp</url>
<title>Zura Bio Limited Class A Ordinary Shares</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares</link>
</image>
<item>
<title>Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-full-year-2025-financial-results-and-recent-corporate-updates</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-full-year-2025-financial-results-and-recent-corporate-updates</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) Topline data expected from the Phase 2</description>
</item>
<item>
<title>Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-to-present-phase-2-tibusure-study-design-poster-evaluating-dual-il-17a-and-baff-inhibition-in-systemic-sclerosis-at-9th-systemic-sclerosis-world-congress-4</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-to-present-phase-2-tibusure-study-design-poster-evaluating-dual-il-17a-and-baff-inhibition-in-systemic-sclerosis-at-9th-systemic-sclerosis-world-congress-4</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated</description>
</item>
<item>
<title>Zura Bio to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Mon, 02 Mar 2026 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., March 02, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that members of its management team will participate in the following upcoming investor conferences:</description>
</item>
<item>
<title>Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-closing-of-its-dollar144-million-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-closing-of-its-dollar144-million-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares</guid>
<pubDate>Fri, 27 Feb 2026 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., February 27, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026.</description>
</item>
<item>
<title>Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-pricing-of-dollar125-million-public-offering-of-class-a-ordinary-shares-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-pricing-of-dollar125-million-public-offering-of-class-a-ordinary-shares-and-pre-funded-warrants</guid>
<pubDate>Wed, 25 Feb 2026 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., February 25, 2026--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that</description>
</item>
<item>
<title>Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-proposed-public-offering-of-class-a-ordinary-shares-and-pre-funded-warrants</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-proposed-public-offering-of-class-a-ordinary-shares-and-pre-funded-warrants</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to</description>
</item>
<item>
<title>Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-welcomes-accomplished-drug-development-leaders-mark-eisner-md-mph-and-ajay-nirula-md-phd-to-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-welcomes-accomplished-drug-development-leaders-mark-eisner-md-mph-and-ajay-nirula-md-phd-to-board-of-directors</guid>
<pubDate>Mon, 23 Feb 2026 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., February 23, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D.,</description>
</item>
<item>
<title>Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-participate-guggenheim-emerging-113000399</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-participate-guggenheim-emerging-113000399</guid>
<pubDate>Wed, 04 Feb 2026 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., February 04, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that its senior leadership team will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026, at 11:00 AM ET in New York, NY. The Co</description>
</item>
<item>
<title>Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-appoints-immunology-industry-135000343</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-appoints-immunology-industry-135000343</guid>
<pubDate>Wed, 21 Jan 2026 13:50:00 GMT</pubDate>
<description>HENDERSON, Nev., January 21, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura.</description>
</item>
<item>
<title>Zura Bio Reports Business Updates and Outlook for 2026</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-business-updates-113000950</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-business-updates-113000950</guid>
<pubDate>Mon, 12 Jan 2026 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., January 12, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported business updates and updated its outlook for 2026.</description>
</item>
<item>
<title>Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-third-quarter-113000967</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-third-quarter-113000967</guid>
<pubDate>Thu, 13 Nov 2025 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., November 13, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates.</description>
</item>
<item>
<title>Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-participate-cantor-fitzgerald-103000240</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-participate-cantor-fitzgerald-103000240</guid>
<pubDate>Wed, 20 Aug 2025 10:30:00 GMT</pubDate>
<description>HENDERSON, Nev., August 20, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor mee</description>
</item>
<item>
<title>Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-second-quarter-121500878</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-second-quarter-121500878</guid>
<pubDate>Thu, 14 Aug 2025 12:15:00 GMT</pubDate>
<description>HENDERSON, Nev., August 14, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates.</description>
</item>
<item>
<title>Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-inducement-grants-203000605</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-inducement-grants-203000605</guid>
<pubDate>Thu, 17 Jul 2025 20:30:00 GMT</pubDate>
<description>HENDERSON, Nev., July 17, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported that on July 15, 2025, the Company granted inducement awards consisting of options to purchase up to 890,950 Class A Ordinary Shares (the "Options") to seven newly hired employees, which includes an award of 672,000 Options granted to Eric Hylleng</description>
</item>
<item>
<title>Zura Bio Announces Chief Financial Officer Transition</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-chief-financial-103000655</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-announces-chief-financial-103000655</guid>
<pubDate>Tue, 01 Jul 2025 10:30:00 GMT</pubDate>
<description>HENDERSON, Nev., July 01, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transitio</description>
</item>
<item>
<title>Zura Bio to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-present-jefferies-global-103000639</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-present-jefferies-global-103000639</guid>
<pubDate>Tue, 27 May 2025 10:30:00 GMT</pubDate>
<description>HENDERSON, Nev., May 27, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present a corporate overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 3:10 PM ET in New York, NY. In addition, the Company will participate in one-on-one meetings</description>
</item>
<item>
<title>Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-launches-global-phase-103000161</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-launches-global-phase-103000161</guid>
<pubDate>Tue, 20 May 2025 10:30:00 GMT</pubDate>
<description>HENDERSON, Nev., May 20, 2025--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.</description>
</item>
<item>
<title>Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-first-quarter-103000198</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-first-quarter-103000198</guid>
<pubDate>Thu, 08 May 2025 10:30:00 GMT</pubDate>
<description>HENDERSON, Nev., May 08, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates.</description>
</item>
<item>
<title>Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-full-2024-103000915</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-reports-full-2024-103000915</guid>
<pubDate>Tue, 25 Mar 2025 10:30:00 GMT</pubDate>
<description>HENDERSON, Nev., March 25, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio" or the "Company"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates.</description>
</item>
<item>
<title>Zura Bio to Present at the Leerink Partners Global Healthcare Conference</title>
<link>https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-present-leerink-partners-113000541</link>
<guid isPermaLink="true">https://6ix.com/company/zura-bio-limited-class-a-ordinary-shares/news/zura-bio-present-leerink-partners-113000541</guid>
<pubDate>Mon, 24 Feb 2025 11:30:00 GMT</pubDate>
<description>HENDERSON, Nev., February 24, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL.</description>
</item>
</channel>
</rss>